Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals perceive the benefits and harms of proactive MASLD screening.
Screening for metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly discussed, but concerns about anxiety, stigma, and overdiagnosis persist. This population-based study from Olmsted County evaluated how individuals perceive the benefits and harms of proactive MASLD screening.
Among 461 screened participants (74% survey response rate), psychological impact was modest. Only 14% reported screening-related anxiety, and 14% were concerned about disclosing a potential diagnosis. Reassurance was substantial: 99% of participants without MASLD felt reassured about their liver health, 48% reported improved quality of life, and 25% adopted healthier lifestyle behaviours.
Among 77 individuals diagnosed with MASLD, 52% experienced some anxiety; however, 95% believed early diagnosis was important to prevent cirrhosis, and 97% valued cardiovascular risk mitigation. Importantly, 79% reported the diagnosis motivated healthier habits, and 30% achieved >10% weight loss following screening.
Overall, perceived benefits—including awareness, lifestyle change, and early prevention—outweighed psychological harms.
Conclusion: Patient-centred MASLD screening appears acceptable and potentially empowering, supporting early detection strategies integrated with structured lifestyle interventions.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.